{"id":11472,"date":"2023-11-16T00:02:00","date_gmt":"2023-11-15T16:02:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11472"},"modified":"2024-11-06T00:05:20","modified_gmt":"2024-11-05T16:05:20","slug":"astellas-pharma-acquires-propella-therapeutics-for-175-million-to-boost-prostate-cancer-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11472","title":{"rendered":"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment"},"content":{"rendered":"\n

Japan\u2019s Astellas Pharma (TYO: 4503<\/a>) has announced the negotiation of a purchase agreement for US biopharmaceutical company Propella Therapeutics this week, with a transaction value of USD 175 million. The deal is anticipated to be finalized by March 2024, subject to the fulfillment of customary conditions. With this acquisition, Astellas will incorporate Propella\u2019s lead candidate, PRL-02 (abiraterone decanoate), a novel androgen biosynthesis inhibitor currently in Phase I of development for metastatic prostate cancer, with expectations to progress to the next stage in the following year.<\/p>\n\n\n\n

Details of the Acquisition<\/strong>
The acquisition of Propella Therapeutics is a strategic move for Astellas Pharma, aimed at enhancing its oncology pipeline. PRL-02 is a significant addition, as it represents a new approach to treating metastatic prostate cancer, a disease with significant unmet medical needs.<\/p>\n\n\n\n

Propella\u2019s Innovative Platform<\/strong>
Propella\u2019s platform is revolutionary in its approach to drug delivery. It transforms existing drugs with proven efficacy but limited by safety concerns into prodrugs. These prodrugs are designed to be delivered and accumulate at the target tissues before releasing the active ingredient. This innovative method bypasses plasma safety limitations and reduces the potential for harm to the liver, offering a promising advancement in drug development.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Japan\u2019s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[353,16,1177],"class_list":["post-11472","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astellas-pharma","tag-cancer","tag-tyo-4503"],"yoast_head":"\nAstellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japan\u2019s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US biopharmaceutical company Propella Therapeutics this week, with a transaction value of USD 175 million. The deal is anticipated to be finalized by March 2024, subject to the fulfillment of customary conditions. With this acquisition, Astellas will incorporate Propella\u2019s lead candidate, PRL-02 (abiraterone decanoate), a novel androgen biosynthesis inhibitor currently in Phase I of development for metastatic prostate cancer, with expectations to progress to the next stage in the following year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11472\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11472\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-15T16:02:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T16:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11472#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11472\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment\",\"datePublished\":\"2023-11-15T16:02:00+00:00\",\"dateModified\":\"2024-11-05T16:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11472\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Astellas Pharma\",\"Cancer\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11472#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11472\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11472\",\"name\":\"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-15T16:02:00+00:00\",\"dateModified\":\"2024-11-05T16:05:20+00:00\",\"description\":\"Japan\u2019s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US biopharmaceutical company Propella Therapeutics this week, with a transaction value of USD 175 million. The deal is anticipated to be finalized by March 2024, subject to the fulfillment of customary conditions. With this acquisition, Astellas will incorporate Propella\u2019s lead candidate, PRL-02 (abiraterone decanoate), a novel androgen biosynthesis inhibitor currently in Phase I of development for metastatic prostate cancer, with expectations to progress to the next stage in the following year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11472#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11472\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11472#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment - Insight, China's Pharmaceutical Industry","description":"Japan\u2019s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US biopharmaceutical company Propella Therapeutics this week, with a transaction value of USD 175 million. The deal is anticipated to be finalized by March 2024, subject to the fulfillment of customary conditions. With this acquisition, Astellas will incorporate Propella\u2019s lead candidate, PRL-02 (abiraterone decanoate), a novel androgen biosynthesis inhibitor currently in Phase I of development for metastatic prostate cancer, with expectations to progress to the next stage in the following year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11472","og_locale":"en_US","og_type":"article","og_title":"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11472","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-15T16:02:00+00:00","article_modified_time":"2024-11-05T16:05:20+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11472#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11472"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment","datePublished":"2023-11-15T16:02:00+00:00","dateModified":"2024-11-05T16:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11472"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Astellas Pharma","Cancer","TYO: 4503"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11472#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11472","url":"https:\/\/flcube.com\/?p=11472","name":"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-15T16:02:00+00:00","dateModified":"2024-11-05T16:05:20+00:00","description":"Japan\u2019s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US biopharmaceutical company Propella Therapeutics this week, with a transaction value of USD 175 million. The deal is anticipated to be finalized by March 2024, subject to the fulfillment of customary conditions. With this acquisition, Astellas will incorporate Propella\u2019s lead candidate, PRL-02 (abiraterone decanoate), a novel androgen biosynthesis inhibitor currently in Phase I of development for metastatic prostate cancer, with expectations to progress to the next stage in the following year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11472#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11472"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11472#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11472"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11472\/revisions"}],"predecessor-version":[{"id":11473,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11472\/revisions\/11473"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}